- Journal List 期刊列表
- Brain 脑
- PMC9976961
作为一个图书馆,NLM 提供科学文献的访问。纳入 NLM 数据库并不意味着认可或同意, NLM 或国立卫生研究院的内容。
Learn more: PMC Disclaimer | PMC Copyright Notice
了解更多: 免责声明 | PMC版权声明
2022 年 10 月 31 日在线发布。doi : 10.1093/brain/awac396
Altered synaptic connectivity in an in vitro human model of STXBP1 encephalopathy
STXBP1 脑病体外人类模型中突触连接的改变
费伊·麦克劳德, 安娜·迪姆齐、艾米·C·马歇尔、大卫·刘易斯·史密斯、里斯·托马斯、加文·J·克劳里、 安德鲁·J·特里维廉
Faye McLeod
Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK
Anna Dimtsi
Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK
Amy C Marshall
Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK
David Lewis-Smith
Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne NE2 4HH, UK
Department of Clinical Neurosciences, Royal Victoria Infirmary, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK
Rhys Thomas
Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne NE2 4HH, UK
Department of Clinical Neurosciences, Royal Victoria Infirmary, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK
Gavin J Clowry
Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK
Andrew J Trevelyan
Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK
作者信息文章注释版权和许可信息PMC 免责声明
Associated Data 相关数据
- Supplementary Materials 补充材料
- GUID: 5E089466-E367-4DC1-8F56-17149E52A4AD
- Data Availability Statement
数据可用性声明 All data generated or analysed and used in this study are available upon reasonable request.
Abstract 抽象的
Early infantile developmental and epileptic encephalopathies are devastating conditions, generally of genetic origin, but the pathological mechanisms often remain obscure. A major obstacle in this field of research is the difficulty of studying cortical brain development in humans, at the relevant time period in utero. To address this, we established an in vitro assay to study the impact of gene variants on the developing human brain by using living organotypic cultures of the human subplate and neighbouring cortical regions, prepared from ethically sourced, 14–17 post-conception week brain tissue (www.hdbr.org). We were able to maintain cultures for several months, during which time the gross anatomical structures of the cortical plate, subplate and marginal zone persisted, while neurons continued to develop morphologically and form new synaptic networks. This preparation thus permits the study of genetic manipulations and their downstream effects on an intact developing human cortical network. We focused on STXBP1 haploinsufficiency, which is among the most common genetic causes of developmental and epileptic encephalopathy. This was induced using shRNA interference, leading to impaired synaptic function and a reduced density of glutamatergic synapses. We thereby provide a critical proof-of-principle for how to study the impact of any gene of interest on the development of the human cortex.
早期婴儿发育性脑病和癫痫性脑病是毁灭性的疾病,通常是遗传性的,但其病理机制往往仍不清楚。该研究领域的一个主要障碍是难以研究人类在子宫内相关时间段的皮质脑发育。为了解决这个问题,我们建立了一种体外测定法,通过使用人类亚板和邻近皮质区域的活器官型培养物来研究基因变异对人类大脑发育的影响,这些器官型培养物是从道德来源的受孕后 14-17 周脑组织中制备的( www.hdbr.org )。我们能够将培养物维持几个月,在此期间,皮质板、亚板和边缘区的总体解剖结构持续存在,而神经元继续在形态上发育并形成新的突触网络。因此,这种准备工作可以研究基因操作及其对完整发育中的人类皮质网络的下游影响。我们重点关注 STXBP1 单倍体不足,这是发育性脑病和癫痫性脑病最常见的遗传原因之一。这是通过 shRNA 干扰诱导的,导致突触功能受损和谷氨酸能突触密度降低。因此,我们为如何研究任何感兴趣的基因对人类皮质发育的影响提供了关键的原理验证。
关键词:人类器官切片,突触,STXBP1,亚板,神经发育
The pathology of genetic epilepsies is likely to begin in utero. McLeod et al. establish an in vitro assay to study the impact of specific gene variants on the developing human brain, using living organotypic slice cultures of the early human cortex, prepared from ethically sourced tissue samples.
遗传性癫痫的病理学很可能在子宫内就开始了。麦克劳德等人。使用由道德来源的组织样本制备的早期人类皮质的活器官切片培养物,建立一种体外测定法,研究特定基因变异对人类大脑发育的影响。
Introduction 介绍
Approximately 1 in 2000 children in the UK develop epilepsy before 3 years of age from a monogenic cause1; of these, about a third will continue to have seizures into adulthood.2 Knowing the genetic cause aids clinical management, yet the true pathological mechanisms remain unknown, at least in part because the aetiology often starts in utero, making their study extremely difficult. A critical phase of prenatal neocortical development is the transient appearance, and subsequent dissolution, of the subplate. This cortical region contains the earliest cortical synaptic network and forms the scaffold for subsequent neocortical development.3,4 It is therefore the site where synaptic malfunction will first disrupt the developing cortex.
在英国,大约每 2000 名儿童中就有 1 人在 3 岁之前因单基因原因患上癫痫症1 ;其中,大约三分之一的人在成年后仍会出现癫痫发作。 2了解遗传原因有助于临床治疗,但真正的病理机制仍然未知,至少部分是因为病因通常始于子宫内,这使得研究极其困难。产前新皮质发育的关键阶段是亚板的短暂出现和随后的溶解。该皮质区域包含最早的皮质突触网络,并形成后续新皮质发育的支架。 3 , 4因此,突触故障首先会在此处破坏正在发育的皮层。
Of particular interest is Syntaxin-binding protein 1 (STXBP1), an essential pre-synaptic protein also called MUNC18-1 (Mammalian uncoordinated-18),5 that is highly expressed in the prenatal developing brain.6 Loss of function variants in STXBP1, collectively termed ‘STXBP1 encephalopathies’, result in significant intellectual disability without regression, early-life onset epilepsy in most, and a range of movement disorders including ataxia, tremor and spasticity,7–9 but the underlying pathological mechanisms are poorly understood. Individuals with protein truncating variants seem to have similar clinical presentations when compared in a large cohort with STXBP1 encephalopathies, suggesting a shared pathological aetiology.10 It seems likely that the effects of STXBP1 haploinsufficiency arise prenatally, supported by the observation that STXBP1 is highly expressed in the developing subplate.6 The study of functional prenatal interactions, however, presents a major practical challenge for early human development.
特别令人感兴趣的是突触结合蛋白 1 (STXBP1),这是一种重要的突触前蛋白,也称为 MUNC18-1(哺乳动物不协调-18) 5 ,在产前发育中的大脑中高度表达。 6 STXBP1功能变异的丧失,统称为“STXBP1 脑病”,会导致严重的智力障碍而不退化,大多数人为早发性癫痫,以及一系列运动障碍,包括共济失调、震颤和痉挛, 7-9病理机制尚不清楚。与一大群 STXBP1 脑病患者相比,具有蛋白质截短变异的个体似乎具有相似的临床表现,这表明存在共同的病理病因。 10 STXBP1 单倍体不足的影响似乎可能在产前出现,STXBP1 在发育中的亚板中高度表达的观察结果支持了这一点。 6然而,功能性产前相互作用的研究对人类早期发育提出了重大的实际挑战。
STXBP1 haploinsufficiency has been replicated in transgenic mouse models and is associated with a post-natal deficit in synaptic neurotransmission.11,12 Rodent models of this condition, however, are limited in one important respect: the rodent subplate is small and very simple in organization, compared with the human subplate,13 calling into question the relevance of these rodent models to human development. Likewise, human cerebral organoids are similarly limited, because, to date, there have been no descriptions of any organoid structures that accurately resemble the subplate as it exists in utero.14
STXBP1 单倍体不足已在转基因小鼠模型中得到复制,并且与出生后突触神经传递缺陷有关。 11 , 12然而,这种情况的啮齿动物模型在一个重要方面受到限制:与人类亚板相比,啮齿动物亚板很小且组织非常简单, 13令人质疑这些啮齿动物模型与人类发展的相关性。同样,人类大脑类器官也同样受到限制,因为迄今为止,还没有任何与子宫内存在的亚板精确相似的类器官结构的描述。 14
To overcome this critical gap in our experimental arsenal, we have developed a protocol for preparing living organotypic cultures of human neocortex, and its underlying subplate, from ethically approved samples of human foetal brain tissue, provided by the MRC-Wellcome Trust Human Developmental Biology Resource (HDBR, www.hdbr.org). Over time, neurons within the culture display evolving morphology, while the culture itself retains its gross anatomical structure. Importantly, the cultures are amenable to genetic manipulation, including knock-down of STXBP1. This is achieved using short hairpin RNA (shRNA) interference, delivered by adeno-associated virus (AAV) viral vectors, to mimic the disease-causing, haploinsufficient state, and by using viral vectors carrying a scrambled STXBP1 sequence as a control. STXBP1 knock-down results in altered synaptic stability and changes in the number of synaptic terminals. We have thus developed a model that is closer to early human neurodevelopment than existing alternatives, and able to facilitate the study of mechanisms suspected of causing neurodevelopmental disorders in humans.
为了克服我们实验库中的这一关键差距,我们开发了一种协议,用于从 MRC-Wellcome Trust 人类发育生物学资源提供的经伦理批准的人类胎儿脑组织样本中制备人类新皮质及其底层亚板的活器官型培养物(HDBR, www.hdbr.org )。随着时间的推移,培养物中的神经元表现出不断变化的形态,而培养物本身则保留其总体解剖结构。重要的是,这些培养物适合基因操作,包括敲低 STXBP1。这是通过使用腺相关病毒 (AAV) 病毒载体传递的短发夹 RNA (shRNA) 干扰来模拟致病的单倍体不足状态,并使用携带乱序STXBP1序列的病毒载体作为对照来实现的。 STXBP1 敲低会导致突触稳定性改变和突触末端数量变化。因此,我们开发了一种比现有替代模型更接近人类早期神经发育的模型,并且能够促进对疑似导致人类神经发育障碍的机制的研究。
Materials and methods
Detailed methods are provided in the Supplementary material.
Human organotypic slice cultures
Human foetal brain tissue was obtained from the joint MRC/Wellcome Trust funded HDBR (https://www.hdbr.org/Project 200428). All tissue was collected with appropriate maternal consent. Ethical approval was granted from the Newcastle and North Tyneside NHS Health Authority Joint Ethics Committee (REC reference: 18/NE/0290). Cultures were prepared from 10 different foetal brains [three from 14 post-conception weeks (pcw), four 16 pcw and three 17 pcw]. Slices were sectioned on a vibratome (280 µm), and then transferred to six-transwell plates containing culture media, which was changed every 2 days. The plates were maintained at 37°C, 5% CO2 in ambient O2 and 90% humidity.
Viral vectors
Three AAV vectors were used:
- Scrambled control shRNA—packaged into an AAV9 vector expressing the cytomegalovirus (CMV) promoter and enhanced green fluorescent protein (eGFP) to achieve a final titre of 5 × 1012 GC/ml. The scrambled target sequence was 5′-CCTAAGGTTAAGTCGCCCTCG-3′. Infected cells were referred to as ‘control’. This virus was purchased from VectorBuilder (VB010000-0023jze).
- STXBP1 shRNA—packaged into an AAV9 vector expressing the cytomegalovirus promoter and eGFP to achieve a final titre of 5 × 1012 GC/ml. The STXBP1 target sequence was 5′TACTGAAGCACAAACATATAT-3′. This virus was purchased from VectorBuilder (VB210925-1040cqu).
- AAV9-CMV-GFP (final titre of 1 × 1013 GC/ml). This virus was made in-house.
Infected cells were identified by their eGFP/GFP tag. At 0 days in vitro (DIV), 3–5 μl of viral vectors were added to the top of each slice. Experiments were conducted up to 4 weeks later for neurite time-lapse experiments, and 2 weeks later for all genetic knock-down conditions.
Live imaging
Live imaging was performed using an inverted Zeiss LSM800 Airyscan confocal microscope. FM4-64 dye was used as previously described15 and analysis was performed using Fiji software (NIH, RRID:SCR_002285).
Whole cell-patch clamp recordings
Slices were transferred into the recording chamber of an upright Leica DMLFSA fluorescent microscope fitted with Micro Control Instruments micromanipulators, and continuously perfused at 34°C with oxygenated artificial CSF. AMPA receptor-mediated miniature glutamatergic post-synaptic currents were recorded at −60 mV in the presence of 100 nM TTX, 10 μM bicuculline and 50 μM AP-5. Miniature GABAergic post-synaptic currents were recorded at 0 mV in the presence of 100 nM TTX and 50 μM AP-5.
Immunohistochemistry
Staining was performed using a protocol optimized specifically for thick slices.16 All primary antibodies used in this study are documented in Supplementary Table 2.
Image acquisition and analysis
Images were acquired on a Zeiss LSM800 Airyscan confocal microscope with fixed settings. The 5× objective [numerical aperture (NA) = 0.16] was used to acquire image stacks (z-step = 5 μm) of general slice anatomy. The 10× objective was used to aid identification of the subplate. This region has an easily identifiable morphology with a sparse cell population in comparison to the neighbouring cortical plate. Subsequently, the 20× objective (NA = 0.8) with ×2 zoom was used to acquire image stacks (z-step = 2 μm) of the infected and non-infected subplate neurons and the 63× objective (NA = 1.4) to acquire image stacks (z-step = 0.25 μm) of synaptic components. Three to four image stacks in the upper part of the subplate (neighbouring the cortical plate) were acquired per slice in a randomized manner. A final image resolution of 1024 × 1024 pixels was obtained.
The number as well as the length of primary subplate neuron processes for scrambled shRNA control and STXBP1 shRNA conditions were measured using Fiji software. Synaptic counts and integrated density (area × mean intensity) measurements were conducted using Zen v.3.1 software (Zeiss; RRID:SCR_013672).
Western blot
Equal homogenate amounts were run on 10% sodium dodecyl–sulphate polyacrylamide gel electrophoresis gel and transferred onto polyvinyl difluoride membranes using BIO-RAD western blot apparatus.
Statistical analysis
Statistical analyses were performed on GraphPad Prism v.9 (RRID:SCR_002798). We assessed data normality using Kolmogorov–Smirnov tests. The appropriate parametric test was used for all normally distributed data, including paired/unpaired t-tests, one-way ANOVA and two-way ANOVA with Tukey’s multiple comparisons test and repeated measures. Statistical significance was accepted as *P < 0.05, **P < 0.01 and ***P < 0.001, and non-significant data are indicated as ns. All data in the results section are presented as ±SEM. Further details of exact sample replicates and statistical tests used are stated in the ‘Results’ section and each figure legend.
Data availability
All data generated or analysed and used in this study are available upon reasonable request.
Results
STXBP1 expression in the developing human brain
We prepared organotypic slice cultures of occipital neocortex and the underlying subplate, from fresh human foetal brain tissue samples from 12 different individuals (Supplementary Table 1). At the time of preparation, the in utero developmental age of the samples was 14–17 pcw. In all cases, the cultures retained the distinct and identifiable anatomical regions of the subplate, its neighbouring cortical plate and the marginal zone (Fig. 1A and B). Synapsin1 immunoreactivity revealed that pre-synaptic terminals were predominantly located in the upper layer of the subplate (adjacent to the cortical plate) at this stage of development (Fig. 1A). The subplate was smallest in 14 pcw samples (n = 3 individual samples; average depth = 308 ± 57 µm), becoming progressively larger in the cultures prepared from 16 pcw (n = 4; 525 ± 11 µm) and 17 pcw brains (n = 3; 651 ± 33 µm) (P < 0.05, one-way ANOVA; Fig. 1B). Similarly, the cortical plate also increased in size from 14 pcw (average depth = 355 ± 26 µm; n = 3) to 17 pcw (477 ± 54 µm; n = 3) (P < 0.05, unpaired t-test; Fig. 1B). STXBP1 showed higher expression at 16–17 pcw, compared to 14 pcw (Fig. 1B), and was observed near spine-like structures and along putative axons of subplate neurons (Fig. 1D). Collectively, these data show that the subplate becomes more prominent and enriched with pre-synaptic proteins including STXBP1 over the 14–17 pcw period.
Synapse maturation in human cortical slice cultures
Given the relatively higher expression of STXBP1 in the subplate at 16–17 pcw and higher density of pre-synaptic terminals in the upper subplate (Fig. 1A), we focused on this age and location for subsequent analysis of how the organotypic cultures continue to develop in vitro. To examine how neuronal morphology developed in the human cortical slice cultures, we infected cultures with viral vectors carrying the eGFP construct. We were able to resolve the neurites of individual labelled neurons and follow their development over intervals of many days to weeks, in vitro. Over these time periods, there was a marked elaboration of the neurite processes (Fig. 1D).
The number of STXBP1 immunoreactive puncta in the subplate more than doubled, between 0 and 27 DIV (16 pcw cultures increase from 4.1 ± 1.6 to 9.0 ± 0.4 puncta/100 µm3; 17 pcw cultures increase from 4.2 ± 0.6 to 13.3 ± 1.1 puncta/100 µm3; Fig. 2A). STXBP1 is localized within glutamatergic and GABAergic pre-synaptic components (Supplementary Fig. 1). We also found significant increases in both glutamatergic synapses (vGlut1 on Homer1 colocalization; 16 pcw cultures increase from 2.7 ± 0.5 to 21.1 ± 1.7 puncta/100 µm3; 17 pcw cultures increase from 9.2 ± 0.9 to 30.3 ± 2.1 puncta/100 µm3; Fig. 2B), and GABAergic synapses (vGAT on gephyrin colocalization; 16 pcw, increase from 0.02 ± 0.02 to 0.2 ± 0.01 puncta/100 µm3; 17 pcw, increase from 0.02 ± 0.02 to 0.5 ± 0.05 puncta/100 µm3; Fig. 2C). These data show that in the human organotypic cultures, subplate neurons continue to mature, making both glutamatergic and GABAergic synapses.
Divergent regulation of synapses with reduced STXBP1 levels
We next investigated the effects of manipulating the expression of STXBP1 in the human cortical slice cultures. We created a generic haplo-insufficiency phenotype for STXBP1 (‘knock-down’) in our human cortical slice cultures using an AAV packaged STXBP1 shRNA in 16 pcw tissue samples, derived from a minimum of three individuals (Fig. 3 and Supplementary Fig. 2). To control for any effects of the viral infection, we performed similar infections with a scrambled STXBP1 sequence, in age matched brain slices (‘scrambled control’). The shRNA achieved ∼50% downregulation of STXBP1 at 14 DIV, compared with the scrambled control cultures prepared from the same brain tissue sample (Fig. 3A). Within the subplate, STXBP1 immunoreactivity was reduced by ∼30%, although there was no overall change in the absolute number of STXBP1 puncta (Supplementary Fig. 3). Since each punctum was presumed to represent a synaptic terminal, this suggests that our shRNA design reduces endogenous STXBP1 protein levels without affecting the total number of STXBP1-positive synaptic terminals.
At 14 DIV, we found no difference in the size of the subplate between control (n = 10 slices, average depth = 529 ± 25 µm) and knock-down cultures (n = 10, average depth = 549 ± 21 µm; P > 0.05, unpaired test). Furthermore, the number and length of neurite processes in subplate neurons in STXBP1 knock-down cultures was indistinguishable (Fig. 3B). In contrast, in these same knock-down cultures, there was a 51% drop in the pre-synaptic vGlut1 puncta (control = 56.8 ± 7.2 puncta/100 µm3; STXBP1 knock-down = 27.8 ± 5.4 puncta/100 µm3) and a 48% drop in the post-synaptic Homer1 puncta (control = 45.8 ± 4.1 puncta/100 µm3; STXBP1 knock-down = 23.6 ± 5.6 puncta/100 µm3) within the subplate region (Supplementary Fig. 4A). We next asked whether there was a concomitant change in the number of co-localized vGlut1 and Homer1 puncta, indicative of full synaptic contact. If the changes in these two proteins occur independently, then one would expect a ∼75% drop in the co-localized proteins; we found an 80% drop (normalized to the control average; 95% confidence intervals = 67–94%), which matched this predicted drop closely (control = 16.7 ± 4.5 puncta/100 µm3; STXBP1 knock-down = 3.3 ± 3.2 puncta/100 µm3; Fig. 3C). To evaluate the functional effects of these anatomical changes, we recorded glutamatergic currents at 14 DIV. The frequency of synaptic events was decreased by 75% in cells expressing STXBP1 shRNA (Fig. 3D).
Remarkably, the genetic manipulation had the opposite effect on GABAergic synapses in cultures undergoing STXBP1 knock-down. There was minimal change in the individual synaptic components (pre-synaptic vGAT: control, 8.4 ± 1.4 puncta/100 µm3, STXBP1 knock-down, 7.2 ± 1.3 puncta/100 µm3; post-synaptic gephyrin: control, 1.07 ± 0.1 puncta/100 µm3, STXBP1 knock-down, 1.3 ± 0.1 puncta/100 µm3; Supplementary Fig. 4B), but there was a large increase in the colocalization of the pre- and post-synaptic expression, indicating there was a doubling of the number of GABAergic synapses in the STXBP1 knock-down cultures (0.09 ± 0.02 puncta/100 µm3) compared with the control cultures (0.04 ± 0.01 puncta/100 µm3; Fig. 3E). There was a parallel ∼1.5-fold increase in the frequency of GABAergic post-synaptic currents (Fig. 3F), compared to scrambled control. There was no change, however, in the amplitude of either glutamatergic or GABAergic currents (Fig. 3D and F). Overall, it seems that reducing STXBP1 expression has no effect on the overall stability of primary subplate neuron neurites but does alter synaptic stability during early subplate development.
Impaired vesicle exocytosis with loss of STXBP1
STXBP1 plays a critical role in synaptic vesicle recycling.17,18 To assess this function, we assayed depletion of fluorescence in tissue that had been loaded with the lipophilic dye, FM4-64. Synaptic vesicles loaded with FM4-64 were identified along isolated axons in the subplate in 16 pcw tissue (Fig. 4A). At 14 DIV, under baseline conditions, signal intensity was reduced by 30% from 0 to 12 s in scrambled controls but not after STXBP1 shRNA knock-down (Fig. 4B), indicating an impairment in spontaneous FM dye unloading at synapses with reduced STXBP1 levels.
In a separate set of brain slices, we assessed evoked exocytosis, by challenging the slices with 50 mM potassium ions, to induce a maximal level of depolarization-induced vesicle exocytosis. The intensity of the signal started to decrease in the first 60 s in scrambled controls but not after STXBP1 shRNA knock-down (Fig. 4C). On K+ stimulation, a 20% reduction in signal intensity was observed in both experimental groups when compared to their pre-evoked levels (Fig. 4C). Given that the magnitude change is the same, this suggests that reduced STXBP1 does not affect evoked FM dye unloading in the subplate under these experimental conditions.
Discussion
We present a novel means of investigating the effect of genetic disorders on prenatal human cortical development that benefits from retaining subplate and cortical plate neuronal networks. This represents a major advance over other approaches, such as human cerebral organoids or induced pluripotent stem cell cultures, neither of which exhibit synaptic circuitry that approaches the complexity of the real in utero networks. In these initial proof-of-principle studies, using a simple shRNA interference genetic manipulation, we demonstrate the divergent effects of STXBP1 haploinsufficiency on glutamatergic and GABAergic synapses at an early stage of brain development. This work will help improve our understanding of the pathological mechanisms underlying certain early infantile onset developmental and epileptic encephalopathies.11
Reduced levels of STXBP1 did not affect the gross morphology of subplate neurons at early developmental stages. Previous studies have shown that absence of UNC-18, the ortholog gene of STXBP1, does not affect neurite length or maintenance in Caenorhabditis elegans18 and that heterozygous Stxbp1 haploinsufficiency does not affect dendrite length17 or cortical neuron density11 in mice postnatally. By addressing these questions in a model closer to the developing human cortex, our data provide confirmatory evidence that these findings are relevant also to the human disorder.
Deficiencies in STXBP1 can result in glutamatergic synaptic neurotransmission dysfunction in rodent models11 and neurons derived from human embryonic stem cells.19 Similarly, we find reduced glutamatergic post-synaptic current frequency, synapse number (equal pre- and post-synaptic component loss) in the human subplate following knock-down of STXBP1. Interestingly, we observed the opposite effect on GABAergic synapses, with an increase both in the frequency of GABAergic synaptic events, and the density of GABAergic synapses. However, there was no change in the absolute number of individual GABAergic pre- and post-synaptic components, suggesting that the coordination of the pre- to post-synaptic elements, to make new synapses, is promoted in the knock-down cultures. STXBP1 is normally present at both GABAergic and glutamatergic synapses, so the divergent effects of STXBP1 knock-down on the two types of synapse was unexpected; given that the two synaptic classes are likely to be regulated in parallel, this divergence may represent a compensatory change manifest in one class, responding to a primary effect in the other. This new finding demonstrates an advantage of our model over previous single cell assays that may not be sensitive to such divergent effects present in an intact neuronal network.
The decrease in frequency of glutamatergic currents and spontaneous FM dye unloading could reflect a decrease in glutamatergic synapses, an impairment in the probability of pre-synaptic neurotransmitter release or, alternatively, a reduction in network excitability. We are unable to distinguish between these possibilities from our experiments. Nonetheless, it is pertinent that our immunohistochemistry data indicate that there is almost an order of magnitude more glutamatergic than GABAergic synapses in the subplate (which is not reflected in the post-synaptic current frequency possibly due to the functional immaturity of the circuit or receptor composition), suggesting that the FM dye labelling is likely to be predominantly of glutamatergic synapses.
Both spontaneous, and evoked neurotransmitter release is affected by lowering the levels of STXBP1 in many animal models.17–20 These results are consistent with the observation that at functioning synapses STXBP1 is crucial for the assembly of the SNARE complex, a collection of proteins involved in the fusion of vesicles with the plasma membrane,21–23 variants in several of which are implicated in neurodevelopmental disorders and epilepsy (collectively, termed SNAREopathies9). In our model system, we did not observe major changes in evoked FM dye unloading. These latter effects may reflect some compensation from other cooperative proteins known to function together to chaperone SNARE assembly, including MUNC13-1.24,25 The experimental paradigm used (elevated extracellular potassium) is also quite extreme, and while this has been used in many previous studies, it is possible that a more physiological assay may yet show an effect in STXBP1 knock-down conditions.26–28
In summary, we present a new experimental approach for understanding human cortical development at a stage approximately equivalent to 14–18 pcw. Loss of STXBP1 at this stage has divergent effects on glutamatergic and GABAergic synapses in the subplate, reducing the former, but increasing the latter. The synaptic networks in this region are proposed to be important for guiding neurogenesis, neuron migration and formation of thalamocortical and cortico-cortical connectivity.4,29,30 Therefore, alterations in subplate synaptic activity are expected to have a large effect on the subsequent development of the forebrain. Treatment of STXBP1-related disorders is challenging, requiring a personalized treatment plan.10 This model system could serve as a crucial bridge to facilitate the development of future precision-medicine approaches.
Acknowledgements
We thank everyone involved in the donation of the foetal tissue samples and the staff of the HDBR for facilitating this. We also would like to acknowledge the advice and assistance from Alex Laude and David Bulmer in the Newcastle University Bioimaging Unit.
Contributor Information
Faye McLeod, Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Anna Dimtsi, Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Amy C Marshall, Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
David Lewis-Smith, Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne NE2 4HH, UK. Department of Clinical Neurosciences, Royal Victoria Infirmary, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK.
Rhys Thomas, Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne NE2 4HH, UK. Department of Clinical Neurosciences, Royal Victoria Infirmary, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK.
Gavin J Clowry, Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Andrew J Trevelyan, Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Funding
This research was funded in whole, or in part, by the Wellcome Trust (grant numbers 102037 and 203914/Z/16/Z) and the Engineering and Physical Sciences Research Council (A000026). For open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. The work of the HDBR was funded by the Wellcome Trust and the Medical Research Council (MR/R006237/1).
Competing interests
R.H.T. has received honoraria and meeting support from Arvelle, Bial, Eisai, GW Pharma, LivaNova, Novartis, Sanofi, UCB Pharma, UNEEG and Zogenix. The other authors report no competing interests.